Navigation Links
Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland
Date:4/4/2019

Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of operations from the National University of Ireland (NUI) Galway campus to become the anchor tenant at the University’s newly created biotechnology park in Galway, Ireland.

“With four clinical trials in full swing and the closing of additional funding rounds to support the development of our novel therapies, we simply needed additional space to accommodate our increasing staff and prepare for our next phase of growth,” said Dr. Larry Couture, CEO of Orbsen Therapeutics. “The move reflects the progress we are making in the development of our therapies, bringing them one step closer to addressing some of today’s most challenging diseases.”

Orbsen Therapeutics’ new global headquarters will combine laboratory and office space on two levels of the park’s inaugural three-story building.

“We are delighted Orbsen Therapeutics was set in motion at NUI Galway and will continue its exciting expansion here in our region,” said David Murphy, Director of the Innovation Office at NUI Galway. “Generating and supporting regional development is central to the University’s strategy. Currently, NUI Galway supports more than 40 companies on campus. Extending the University’s incubation eco-system will allow us to amplify efforts and enable even more start-up companies to innovate and grow.”  

Orbsen’s proprietary ORBCEL™ immunotherapy yields nearly 100 percent pure stromal cells, a significant increase in purity when compared to first generation stromal cell therapies.

Orbsen currently is enrolling and treating patients in four clinical trials to assess ORBCEL’s safety and efficacy in the prevention and treatment of diabetic kidney disease, non-healing diabetic foot ulcers, moderate to severe acute respiratory distress syndrome (ARDS) and in patients with primary sclerosis cholangitis (PSC) and autoimmune hepatitis. A fifth trial is pending for patients with several auto-immune disorders.

Orbsen’s new headquarters will be the hub of operations to coordinate research, operations, product development and clinical development.

About Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of cellular immunotherapies across four immune-mediated inflammatory conditions. Founded in 2006, Orbsen Therapeutics Ltd., is a privately held company led by global leaders in the field of cellular immunotherapy. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University or Ireland Galway, has developed proprietary technologies that enables the isolation of a well characterized population of pure stromal cells from human tissues which, once isolated, can be expanded and frozen to generate multiple doses of a high-margin, “off the shelf” therapeutic product.

For more information visit: http://www.orbsentherapeutics.com

Read the full story at https://www.prweb.com/releases/orbsen_therapeutics_moves_into_new_headquarters_in_galway_ireland/prweb16211996.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Orbsen Therapeutics' NEPHSTROM Clinical Trial Underway at Four European Union Locations
2. Nativis Announces Name Change To EMulate Therapeutics, Inc.
3. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
4. RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
5. Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
6. Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
7. Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
8. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
9. Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
10. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2019)... ... April 30, 2019 , ... ... Cambridge, MA, announces today that Holotype HLA and other Omixon products will be ... Federation for Immunogenetics (EFI) in Lisbon, Portugal. Among the major scientific events, ...
(Date:5/2/2019)... ... May 01, 2019 , ... ... Directors has appointed John Rakow, the Company’s General Counsel, as Interim Chief Executive ... Zac Apte, are currently on administrative leave. There will also be an independent ...
(Date:4/27/2019)... (PRWEB) , ... April 26, 2019 , ... ... Business Plan Competition on Thursday, April 25. More than 30 student venture teams, ... in-kind prizes totaling more than $75,000. , The top five teams in ...
Breaking Biology News(10 mins):
(Date:5/2/2019)... ... April 30, 2019 , ... ... REPROCELL USA Inc. has demonstrated its ability to provide various services and ... to enhance customer satisfaction through the effective implementation of its quality management ...
(Date:5/2/2019)... ... 02, 2019 , ... Stay on top of current hot topics through free ... to all webinars is free, so be sure to register today to save your ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS , May 7 – ...
(Date:5/2/2019)... ... May 02, 2019 , ... Boston Robotic Hair Restoration ... Gone are the days of painful hair transplant procedures. Boston Robotic Hair Restoration ... the only robotic intelligent solution to offer a minimally invasive procedure. With the ...
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions ... service organizations, today announced global availability of Inference Studio’s latest version, which makes ... sizes to harness the power of Google’s Contact Center AI (CCAI). ...
Breaking Biology Technology: